Severity of Non-B and Non-C Hepatitis Versus Hepatitis B and C Associated Chronic Liver Disease: A Retrospective,

Muhammad Sohaib Asghar1, Muhammad Nadeem Ahsan2, Uzma Rasheed3

  • 1Internal Medicine, Dow University of Health Sciences, Karachi, PAK.

Cureus
|February 1, 2021
PubMed

Insights

This study found that non-hepatitis B, C associated Chronic Liver Disease (CLD) has a higher mortality risk in severe stages (Child-Pugh class C), indicated by higher MELD scores. Biochemical markers also correlate with CLD severity across different etiologies.

Area of Science:

  • Hepatology
  • Internal Medicine
  • Clinical Research

Background:

  • Chronic Liver Disease (CLD) has diverse causes including viral hepatitis, alcohol abuse, and non-alcoholic fatty liver disease.
  • The Child-Pugh scoring system assesses cirrhosis prognosis and mortality risk.
  • Understanding etiological differences in CLD severity and mortality is crucial for patient management.

Purpose of the Study:

  • To evaluate mortality risks associated with various CLD etiologies.
  • To identify biochemical markers correlating with CLD severity.
  • To compare Model for End-Stage Liver Disease (MELD) scores across CLD groups and Child-Pugh classifications.

Main Methods:

  • Retrospective study of 167 CLD patients (July-Dec 2019).
  • Etiologies categorized into hepatitis B, C-CLD and non-hepatitis B, C-CLD groups.
  • Statistical analysis included independent sample t-tests and chi-square/Fisher's exact tests (p<0.05 significance).

Main Results:

  • No significant gender or age differences between CLD groups.
  • Non-hepatitis B, C-CLD showed significant association with comorbidities like diabetes and hypertension.
  • While bilirubin and creatinine levels were higher in non-hepatitis B, C-CLD, MELD scores were significantly higher in Child-Pugh class C non-hepatitis B, C-CLD patients.

Conclusions:

  • Non-hepatitis B, C-CLD presents as milder in early stages (Child-Pugh A) but carries increased mortality risk in advanced stages (Child-Pugh C).
  • MELD scores are significantly higher in severe non-hepatitis B, C-CLD, indicating greater mortality risk.
  • The study identified key biochemical markers associated with CLD severity across different etiologies.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
79
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.6K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
104
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
81